What is the price target for AGIO stock?
16 analysts have analysed AGIO and the average price target is 40.8 USD. This implies a price increase of 46.5% is expected in the next year compared to the current price of 27.85.
AGIOS PHARMACEUTICALS INC (AGIO) Forecast, Price Target & Analyst Ratings
NASDAQ:AGIO • US00847X1046
Current stock price
27.85 USD
+0.26 (+0.94%)
At close:
27.85 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AGIOS PHARMACEUTICALS INC (AGIO).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Apr 29, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.83
- Revenue Estimate
- 14.227M
Price Target Details & History
Consensus Price Target and Range
Mean target
$40.80
Upside
+ 46.50%
From current price of $27.85 to mean target of $40.80, Based on 16 analyst forecasts
Low
$28.28
Median
$38.76
High
$68.25
Price Target Revisions
1 Month
4.09%
3 Months
24.51%
Price Target Summary
16 Wall Street analysts provided a forecast for the next 12 months for AGIO. The average price target is 40.8 USD. This implies a price increase of 46.5% is expected in the next year compared to the current price of 27.85.
The average price target has been revised upward by 24.51% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.25%
AGIO was analyzed by 16 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about AGIO.
In the previous month the buy percentage consensus was at a similar level.
AGIO was analyzed by 16 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-05 | Citigroup | Maintains | Buy -> Buy |
| 2026-02-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-06 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-12-26 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-12-24 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-24 | B of A Securities | Maintains | Buy -> Buy |
| 2025-12-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-26 | Citigroup | Initiate | Buy |
| 2025-11-24 | Truist Securities | Initiate | Buy |
| 2025-11-21 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-11-20 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-11-20 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2025-11-20 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-11-20 | B of A Securities | Maintains | Buy -> Buy |
| 2025-11-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-28 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-07-22 | B of A Securities | Maintains | Buy -> Buy |
| 2025-05-02 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-02-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-18 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-12-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-12-09 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-11-01 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-11-01 | RBC Capital | Reiterate | Outperform -> Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 29, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.83
- Revenue Estimate
- 14.227M
- Revenue Q2Q
- 63.04%
- EPS Q2Q
- -18.31%
- Number of Analysts
- 12
Next Earnings Revisions
Revenue (1 Month)
-10.60%
Revenue (3 Months)
-11.63%
EPS (1 Month)
1.85%
EPS (3 Months)
4.58%
Next Earnings Summary
AGIO is expected to report earnings on 4/29/2026. The consensus EPS estimate for the next earnings is -1.83 USD and the consensus revenue estimate is 14.23M USD.
The next earnings revenue estimate has been revised downward by 11.63% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 26.823M 88.36% | 36.498M 36.07% | 54.028M 48.03% | 94.916M 75.68% | 254.02M 167.63% | 392.14M 54.37% | 508.98M 29.80% | 676.06M 32.83% | 729.57M 7.91% | 857.4M 17.52% | 990.31M 15.50% | |
| EBITDA YoY % growth | -384.864M -1.15% | -420.084M -9.15% | -466.955M -11.16% | -450.894M 3.44% | -333.851M 25.96% | -165.783M 50.34% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -391.487M -0.63% | -425.737M -8.75% | -472.132M -10.90% | -450.197M 4.65% | -356.652M 20.78% | -236.899M 33.58% | -192.618M 18.69% | -36.193M 81.21% | -48.434M -33.82% | 63.279M 230.65% | 185.41M 193.00% | |
| Operating Margin | -1,459.52% | -1,166.47% | -873.87% | -474.31% | -140.40% | -60.41% | -37.84% | -5.35% | -6.64% | 7.38% | 18.72% | |
| EPS YoY % growth | -6.34 -49.53% | -7.00 -10.35% | -7.12 -1.77% | -6.74 5.34% | -5.17 23.33% | -3.32 35.77% | -2.45 26.06% | -0.11 95.34% | -0.04 67.23% | 1.33 3,660.49% | 2.78 108.67% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -1.83 -18.31% | -1.74 9.69% | -1.72 3.42% | -1.81 2.50% |
| Revenue Q2Q % growth | 14.227M 63.04% | 20.41M 63.87% | 30.104M 133.73% | 37.434M 87.17% |
| EBITDA Q2Q % growth | -122.195M -15.99% | -119.701M 3.87% | -127.88M -13.21% | N/A |
| EBIT Q2Q % growth | -120.902M -13.39% | -115.379M 9.19% | -128.122M -9.63% | -138.924M -14.27% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
15.33%
EPS Next 5 Year
14.68%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
103.32%
Revenue Next 5 Year
70.69%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
18.41%
EBIT Next 5 Year
N/A
AGIOS PHARMACEUTICALS INC / AGIO Forecast FAQ
When does AGIOS PHARMACEUTICALS INC (AGIO) report earnings?
AGIOS PHARMACEUTICALS INC (AGIO) will report earnings on 2026-04-29.
Can you provide the consensus estimates for AGIOS PHARMACEUTICALS INC next earnings?
The consensus EPS estimate for the next earnings of AGIOS PHARMACEUTICALS INC (AGIO) is -1.83 USD and the consensus revenue estimate is 14.23M USD.
How many analysts cover AGIOS PHARMACEUTICALS INC (AGIO) stock?
The number of analysts covering AGIOS PHARMACEUTICALS INC (AGIO) is 16.